IP Library Granted Patent US 9,315,843
Granted Patent B2
US 9,315,843 · App. 14/080,114 · Granted Apr 19, 2016

Methods of producing hybrid antibodies

Inventors: Andrew J. Murphy (Croton-On-Hudson, NY); George D. Yancopoulos (Yorktown Heights, NY); Margaret Karow (Santa Rosa, CA); Lynn Macdonald (White Plains, NY); Sean Stevens (San Diego, CA); Aris N. Economides (Tarrytown, NY); David M. Valenzuela (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12P21/00A01K67/0275A01K67/0278C07K16/00C07K16/28C07K16/462C12N15/67C12N15/85C12N15/8509C12N15/902C12N15/907A01K2217/05A01K2227/105C07K2317/56C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,315,843
App. No.
14/080,114
Granted
Apr 19, 2016
Kind
B2
Abstract

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Claims (20)

1. A method of producing an antibody having a human immunoglobulin heavy chain variable region and a human heavy chain constant region, the method comprising:

(a) providing a transgenic mouse whose genome comprises in its germline human unrearranged immunoglobulin heavy chain V, D, and J gene segments, wherein the human unrearranged heavy chain V, D, and J gene segments in situ replace mouse endogenous immunoglobulin heavy chain V, D, and J gene segments, and the human unrearranged immunoglobulin heavy chain V, D, and J gene segments are operably linked to an endogenous mouse heavy chain constant region gene, wherein the mouse heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein rearrangement of the human heavy chain V, D, and J gene segments in the mouse results in a rearranged human heavy chain variable region gene linked to the mouse heavy chain constant region gene, wherein the mouse in response to the antigen produces a hybrid antibody that comprises a human heavy chain variable region encoded by the rearranged human heavy chain variable region gene and a mouse heavy chain constant region encoded by the mouse heavy chain constant region gene, and wherein the mouse does not produce fully human antibodies;

(b) stimulating an immune response in the mouse by exposing the mouse to an antigen;

(c) preparing a hybridoma expressing the hybrid antibody from the spleen of the mouse stimulated with the antigen in step (b);

(d) isolating DNA encoding the human heavy chain variable region of the hybrid antibody from the hydridoma of step (c);

(e) operably linking the DNA encoding the human heavy chain variable region of the hybrid antibody to DNA encoding a human heavy chain constant region in a cell;

(f) growing the cell under conditions such that the cell expresses an antibody comprising the human heavy chain variable region and the human heavy chain constant region; and

(g) recovering the antibody.

2. The method of claim 1 , wherein the mouse constant region gene consists of a murine Fc region.

3. A method of producing an antibody having a human immunoglobulin heavy chain variable region and a human heavy chain constant region, the method comprising:

(a) providing a transgenic mouse whose genome comprises in its germline human unrearranged immunoglobulin heavy chain V, D, and J gene segments, wherein the human unrearranged heavy chain V, D, and J gene segments in situ replace mouse endogenous immunoglobulin heavy chain V, D, and J gene segments, and the human unrearranged immunoglobulin heavy chain V, D, and J gene segments are operably linked to an endogenous mouse heavy chain constant region gene, wherein the mouse heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein rearrangement of the human heavy chain V, D, and J gene segments in the mouse results in a rearranged human heavy chain gene linked to the mouse heavy chain constant region gene, wherein the mouse in response to an antigen produces a hybrid antibody that comprises a human heavy chain variable region encoded by the rearranged human heavy chain variable region gene and a mouse heavy chain constant region encoded by the mouse heavy chain constant region gene, and wherein the mouse does not produce fully human antibodies;

(b) stimulating an immune response in the mouse by exposing the mouse to an antigen;

(c) isolating DNA encoding the human heavy chain variable region of the hybrid antibody from the mouse stimulated with the antigen in step (b);

(d) operably linking the DNA encoding the human heavy chain variable region of the hybrid antibody to DNA encoding a human heavy chain constant region in a cell;

(e) growing the cell under conditions such that the cell expresses an antibody comprising the human heavy chain variable region and the human heavy chain constant region; and

(f) recovering the antibody.

4. The method of claim 3 , wherein the mouse heavy chain constant region gene consists of a murine Fc region.

5. The method of claim 3 , wherein the DNA encoding the human heavy chain variable region of the antibody is isolated in step (c) by PCR amplification or cDNA cloning.

6. The method of claim 1 , wherein the cell is a CHO cell.

7. The method of claim 1 , wherein the DNA encoding the human heavy chain variable region of the antibody is isolated in step (d) by PCR amplification or cDNA cloning.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: ECONOMIDES, ARIS N.; VALENZUELA, DAVID M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 032738/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: MURPHY, ANDREW J.; YANCOPOULOS, GEORGE D.; KAROW, MARGARET; MACDONALD, LYNN; STEVENS, SEAN
To: REGENERON PHARMACEUTICALS INC.
Reel/Frame 032406/0956 →
Continuity (9)
Continuation 13719819 · Dec 19, 2012
Continuation 13154976 · Jun 7, 2011
Continuation 11595427 · Nov 9, 2006
Continuation 10624044 · Jul 21, 2003
Division 09784859 · Feb 16, 2001
Division 14080114
Continuation 13719842 · Dec 19, 2012
Continuation 13154976
Related Publication 20140073010A1 · Mar 13, 2014